Timing matters: study tests if starting gout drug during a flare is safe

NCT ID NCT07661030

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares starting dotinurad, a urate-lowering drug, during an acute gout flare versus waiting until the flare resolves. About 142 adults with gout will be randomly assigned to one of two timing schedules. Researchers will measure how quickly the flare resolves and whether starting early increases pain or inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dotinurad

What this could lead to

If successful, this could show that starting urate-lowering therapy during a gout flare is safe and does not worsen pain or inflammation, allowing earlier treatment.

What could go wrong

This is a phase 4 trial with a moderate number of participants. It may not prove long-term benefits, and some patients might experience increased pain or flare recurrence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.